Modality
Bispecific Ab
MOA
CD47i
Target
KIF18A
Pathway
T-cell
EoEFabryCervical Ca
Development Pipeline
Preclinical
~Dec 2023
→ ~Mar 2025
Phase 1
Jun 2025
Phase 1Current
NCT07858611
2,652 pts·Cervical Ca
2025-06→TBD·Completed
2,652 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P1/2
Complet…
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07858611 | Phase 1/2 | Cervical Ca | Completed | 2652 | HbA1c |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| Cevizanubrutinib | Johnson & Johnson | Preclinical | FcRn | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| AZN-6294 | AstraZeneca | Phase 2/3 | APOC3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| BGN-3859 | BeiGene | Approved | PSMA |